---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000054"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-09-09T11:43:19+00:00"
generated_at: "2026-09-09T11:45:05.267514+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina's SER-252 Phase 1b Cohort 1 clears safety review; advances to Cohort 2

## Summary
- Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety/tolerability data.
- Cohort 1 (lowest dose, n=8) showed sustained apomorphine exposure and motor function improvements in individual patients.
- Topline data from single-ascending-dose portion expected in first half of 2027.
- Study is randomized, double-blind, placebo-controlled; 5 cohorts of 8 in SAD portion, then MAD portion.

## SEC filing metadata
- accession: 0001708599-26-000054
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-09-09T11:43:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/0001708599-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/ser-20260909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000054
- JSON: https://secwatch.observer/filing/0001708599-26-000054.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.